In The News: School of Integrated Health Sciences
Most people in the United States don’t consume enough whole grains. And that’s a problem, experts say.
Struggling to fit workouts into your busy week? You’re not alone. New research suggests that “weekend warriors” who pack at least 150 minutes of exercise into one or two days enjoy similar health benefits to those who spread workouts throughout the week. Both groups had reduced risks for over 260 diseases, including diabetes, hypertension, and mental health conditions, the findings showed.
What is rhabdomyolysis and how do you recognize it? Let's start with a practical case. It seemed that Chris Thornham had found the perfect training regime for his needs. At the time, he was working with a fitness coach who usually trains cyclists and 15 hours of his week were devoted to training for a 200-kilometer mountain bike race, which was routine for an exceptional guy like him.
Working a desk job is a reliable way to get your bag, but not so much your steps. That is, unless you’re privy to the best under desk treadmills, which allow you to take hot girl walks while clearing your inbox or participating in Zoom calls.
If it feels like you’ve been noticing more body-weight workout content on your social feeds—the kinds of exercises your grandfather might have done in gym class—you’re not imagining things. Fitness, like fashion, is cyclical. As sure as skinny jeans will be cool again, you can bet that training styles like calisthenics will always come back around. But this isn’t about nostalgia. Whether we’re talking about bringing back your grandfather’s workout or his gym shorts, it has to hold up in the present day. And in the case of calisthenics, it totally makes sense why this is happening right now.
The Alzheimer's Drug Discovery Foundation (ADDF) will be leading a roundtable, "Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments," at the 2024 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 29th through November 1st in Madrid, Spain.
UNLV recently received a $1.5 million grant from the U.S. Department of Energy to study the effects of radiation exposure and the risk of breast cancer in occupational and medical radiation.
Stranded on a desert island, I could live off nothing but bread, bananas and broccoli. That’s what I say, anyway. My wife scoffs. What about protein? Hmm, beans, I suppose, sticking stubbornly to my B-inspired list. But I’m no nutritionist. And like many people, I’m often confused by the competing and conflicting claims about what we should eat.
The Alzheimer's Drug Discovery Foundation (ADDF) today announced a new investment to develop a first-of-its-kind Biomarker Observatory that will provide a comprehensive overview of the Alzheimer's biomarkers pipeline, including blood tests, brain scans, digital devices, and other tools that can help diagnose and monitor the disease. These efforts will be led by renowned clinical trialist Jeffrey Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at ҳ| 鶹ýӳ with Co-Principal Investigator Feixiong Cheng, PhD, from the Laboratory of Network Medicine at Cleveland Clinic. This Observatory will fill a critical gap by creating the first thorough overview of the biomarker pipeline, serving as a key resource to catalyze progress in drug development.
Today, Global Alzheimer’s Platform Foundation® (GAP) and the ҳ| 鶹ýӳ (UNLV), announced a memorandum of understanding (MOU) regarding a collaboration to accelerate research for neurodegenerative diseases. This includes establishing a state-of-the-art imaging and emerging technology program dedicated to the development and implementation of new and innovative biomarker and diagnostic solutions for central nervous system (CNS) research.
Over the past two years, Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla, both anti-amyloid antibodies, made history as the first real options to slow cognitive decline associated with Alzheimer’s disease. For years, amyloid plaques and tau tangles have been a primary target of Alzheimer’s disease research and drug development, but while affecting these proteins may yield some benefit, the illness continues to progress. Today, multiple therapeutics are in Phase III trials with other targets, suggesting that within the next few years it may become possible to treat Alzheimer’s via multiple pathways.
I love to run—but I detest running uphill. When I hit an incline, my legs burn, I get acid reflux, and I often need to take a break to catch my breath. Jogging over hills is so terrible for me that I exclusively map out flat routes and sign up for races with minimal elevation, if any. As it turns out, there’s a legitimate reason people struggle with hills. Every single one of us has a unique running style, or running fingerprint, as John Mercer, a professor of Kinesiology and Nutrition Sciences at the ҳ| 鶹ýӳ, calls it.